Lord, Abbett & Co. LLC Fibrogen Inc Transaction History

Lord, Abbett & Co. LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$35.13 - $55.53 $5.23 Million - $8.26 Million	-148,780 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$42.83 - $59.91 $207,168 - $289,784	-4,837 Reduced 3.15%	148,780 $8.09 Million
Q4 2018 Feb 14, 2019	SELL	$37.97 - $60.16 $13.6 Million - $21.5 Million	-357,503 Reduced 69.95%	153,617 $7.11 Million
Q3 2018 Nov 14, 2018	SELL	$56.3 - $67.25 $6.1 Million - $7.29 Million	-108,380 Reduced 17.49%	511,120 $31.1 Million
Q2 2018 Aug 14, 2018	BUY	$44.9 - $64.95 $1.81 Million - $2.61 Million	40,211 Added 6.94%	619,500 $38.8 Million
Q1 2018 May 15, 2018	BUY	$45.35 - $61.65 $5.45 Million - $7.41 Million	120,258 Added 26.2%	579,289 $26.8 Million
Q4 2017 Feb 14, 2018	SELL	$41.95 - $60.1 $2.29 Million - $3.27 Million	-54,492 Reduced 10.61%	459,031 $21.8 Million
Q3 2017 Nov 14, 2017	BUY	$33.4 - $53.9 $17.2 Million - $27.7 Million	513,523	513,523 $27.6 Million

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.